RecruitingNCT02880618

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System

Sponsor

CVRx, Inc.

Enrollment

500 participants

Start Date

Dec 13, 2016

Study Type

OBSERVATIONAL

Conditions

Heart Failure

Summary

The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Barostim Neo™ System for people with heart failure. The study is currently recruiting participants at 30 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBarostim Neo™ System

Locations(30)

Albertinen-Krankenhaus

Hamburg, Free and Hanseatic City of Hamburg, Germany

Herzzentrum Bad Oyenhausen

Bad Oeynhausen, Germany

Berlin Charité & Deutschen Herzzentrum Berlin

Berlin, Germany

Charité Campus Virchow Klinikum

Berlin, Germany

Immanuel Klinikum Bernau Herzzentrum Brandenburg

Bernau, Germany

Medizinisches Versorgungszentrum am Küchwald GmbH

Chemnitz, Germany

Universitätsklinikum Köln Herzzentrum

Cologne, Germany

Lippe Klinikum

Detmold, Germany

Dresden Friedrichstadt

Dresden, Germany

Herzzentrum Dresden - Interventionelle Kardiologie

Dresden, Germany

Herzzentrum Dresden, Elektrophysiologie

Dresden, Germany

Uniklinik Frankfurt

Frankfurt, Germany

Universitätsklinikum Gießen und Marburg

Giessen, Germany

Herzzentrum Göttingen

Göttingen, Germany

Asklepios Klinik Altona

Hamburg, Germany

St. Barbara Klinik Hamm

Hamm, Germany

Medizinische Hochschule Hannover

Hanover, Germany

Kardiologie im Klinikum Ingolstadt

Ingolstadt, Germany

Universitätsklinikum Schleswig-Holstein Campus Kiel

Kiel, Germany

Herzentrum Lahr

Lahr, Germany

Universitätsklinikum Leipzig

Leipzig, Germany

Leipzig St. Georg

Leipzig, Germany

Universitätsklinik Mainz

Mainz, Germany

Clemenshospital Münster

Münster, Germany

St. Vincenz-Krankenhaus

Paderborn, Germany

Universitätsklinikum Regensburg

Regensburg, Germany

Marienkrankenhaus Siegen

Siegen, Germany

Krankenhaus & MVZ Maria-Hilf Stadtlohn GmbH

Stadtlohn, Germany

Klinikum Tuttlingen

Tuttlingen, Germany

Fondazione di Ricerca e Cura "Giovanni Paolo II"

Campobasso, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02880618

Related Trials

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060953 locations

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

NCT072320302 locations

RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases

NCT07491237

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197315 locations

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT0631003137 locations